# EDGAR Filing Document

**Accession Number:** 0001821586
**File Stem:** 0001104659-23-007190
**Filing Date:** 2023-1
**Character Count:** 23557
**Document Hash:** 22cf22ba2833d425fec6b0186c941c8b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-007190.hdr.sgml**: 20230127

**ACCESSION NUMBER**: 0001104659-23-007190

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230127

**DATE AS OF CHANGE**: 20230127

**GROUP MEMBERS**: E.MERCK KG

**GROUP MEMBERS**: MERCK KGAA

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MoonLake Immunotherapeutics
- **CENTRAL INDEX KEY:** 0001821586
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91803
- **FILM NUMBER:** 23559574

**BUSINESS ADDRESS:**
- **STREET 1:** DORFSTRASSE 29
- **CITY:** ZUG
- **STATE:** V8
- **ZIP:** 6300
- **BUSINESS PHONE:** 41 41 510 8022

**MAIL ADDRESS:**
- **STREET 1:** DORFSTRASSE 29
- **CITY:** ZUG
- **STATE:** V8
- **ZIP:** 6300

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Helix Acquisition Corp
- **DATE OF NAME CHANGE:** 20200818
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Merck Healthcare KGaA
- **CENTRAL INDEX KEY:** 0001923120
- **IRS NUMBER:** 981634883
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** FRANKFURTER STRASSE 250
- **STREET 2:** POSTFACH 64271
- **CITY:** DARMSTADT
- **STATE:** 2M
- **ZIP:** 64293
- **BUSINESS PHONE:** 49 6151 72 0

**MAIL ADDRESS:**
- **STREET 1:** FRANKFURTER STRASSE 250
- **STREET 2:** POSTFACH 64271
- **CITY:** DARMSTADT
- **STATE:** 2M
- **ZIP:** 64293

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

SCHEDULE 13G

(Rule 13d-102)

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT**

**TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED** 

**PURSUANT TO § 240.13d-2**

**(Amendment No. 1)\***

---

| |
|:---|
| MoonLake Immunotherapeutics |
| (Name of Issuer) |
| Class A ordinary share, par value $0.0001 per share |
| (Title of Class of Securities) |
| G4444C102 |
| (CUSIP Number) |
| 31 December 2022 |
| (Date of Event Which Requires Filing of the Statement) |

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

⌧ Rule 13d-1(c)

□ Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Cusip No. G4444C102 | &nbsp;&nbsp;**13G** | &nbsp;&nbsp;Page 2 of 7 Pages |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. NAME OF REPORTING PERSONS Merck Healthcare KGaA, Darmstadt Germany an affiliate of Merck KGaA,
 Darmstadt, Germany

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) □ (b) □

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION Germany

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; 5.<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SOLE VOTING POWER<br> 3,330,231<sup>[1]</sup><br>|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; 6.<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SHARED VOTING POWER<br> 0<br>|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; 7.<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SOLE DISPOSITIVE POWER<br> 3,330,231 <sup>1</sup><br>|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; 8.<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SHARED DISPOSITIVE POWER<br> 0 <br>|

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,330,231 <sup>1</sup>

10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE
 INSTRUCTIONS) □

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.9% <sup>[2]</sup>

12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO

------

<sup>[1]</sup> The record holder of the securities covered by this Schedule 13G is Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA Darmstadt, Germany. Merck Healthcare KGaA, Darmstadt Germany is a dominantly controlled subsidiary of Merck KGaA, Darmstadt, Germany and E.Merck KG, Darmstadt Germany. Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 40) and the beneficiary of Merck Healthcare KGaA, Darmstadt Germany. Merck KGaA, Darmstadt Germany is dominantly controlled by E.Merck KG, Darmstadt Germany. Merck Healthcare KGaA, Darmstadt Germany, currently holds 3,330,231 Class C ordinary shares of the Issuer (the "Class C Shares") and 99,000 Common Shares of MoonLake Immunotherapeutics AG, a Swiss stock corporation and subsidiary of the Issuer (the "Common Shares"). Pursuant to the terms of that certain Restated and Amended Shareholders' Agreement, dated April 5, 2022, between the Issuer, MoonLake Immunotherapeutics AG, Merck Healthcare KGaA, Darmstadt Germany, and the other parties named therein, which was attached as Exhibit 10.2 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 11, 2022 (the "Issuer Form 8-K") and is incorporated by reference herein, Merck Healthcare KGaA has the right, commencing on October 05, 2022, to exchange such Common Shares for 3,330,231 Class A ordinary shares of the Issuer (assuming exercise of such exchange right with respect to all Common Shares held by Merck Healthcare KGaA), whereupon a number of Class C Shares belonging to Merck Healthcare KGaA equal to the number of Class A ordinary shares to be received by Merck Healthcare KGaA shall be surrendered by Merck Healthcare KGaA and, on surrender, automatically cancelled by the Issuer

<sup>[2]</sup> This percentage assumes exchange of all Common Shares and surrender of all Class C Shares held by Merck Healthcare KGaA, Darmstadt Germany for a total of 3,330,231 Class A ordinary shares and is based upon 38,977,600 Class A ordinary shares outstanding as of November 14 2022 as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022. As of the date of this filing, the Class C shares held by Merck Healthcare KGaA, Darmstadt Germany represent 6.3% of the Issuer's total voting ordinary shares based upon 52,701,111 voting ordinary shares outstanding as of November 14, 2022 as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022, of which 38,977,600 shares were Class A ordinary shares and 13,723,511 shares were Class C ordinary shares.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Cusip No. G4444C102 | &nbsp;&nbsp;**13G** | &nbsp;&nbsp;Page 3 of 7 Pages |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. NAME OF REPORTING PERSONS Merck KGaA, Darmstadt, Germany

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) □ (b) □

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION Germany

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; 5.<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SOLE VOTING POWER<br> 3,330,231<sup>[3]</sup><br>|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; 6.<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SHARED VOTING POWER<br> 0<br>|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; 7.<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SOLE DISPOSITIVE POWER<br> 3,330,231<sup>3</sup> <br>|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; 8.<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SHARED DISPOSITIVE POWER<br> 0 <br>|

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,330,231<sup>3</sup>

10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE
 INSTRUCTIONS) □

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.9% <sup>[4]</sup>

12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO

------

<sup>[3]</sup> The record holder of the securities covered by this Schedule 13G is Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA Darmstadt, Germany. Merck Healthcare KGaA, Darmstadt Germany is a dominantly controlled subsidiary of Merck KGaA, Darmstadt, Germany and E.Merck KG, Darmstadt Germany. Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 40) and the beneficiary of Merck Healthcare KGaA, Darmstadt Germany. Merck KGaA, Darmstadt Germany is dominantly controlled by E.Merck KG, Darmstadt Germany. Merck Healthcare KGaA, Darmstadt Germany, currently holds 3,330,231 Class C ordinary shares of the Issuer (the "Class C Shares") and 99,000 Common Shares of MoonLake Immunotherapeutics AG, a Swiss stock corporation and subsidiary of the Issuer (the "Common Shares"). Pursuant to the terms of that certain Restated and Amended Shareholders' Agreement, dated April 5, 2022, between the Issuer, MoonLake Immunotherapeutics AG, Merck Healthcare KGaA, Darmstadt Germany, and the other parties named therein, which was attached as Exhibit 10.2 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 11, 2022 (the "Issuer Form 8-K") and is incorporated by reference herein, Merck Healthcare KGaA has the right, commencing October 05, 2022, to exchange such Common Shares for 3,330,231 Class A ordinary shares of the Issuer (assuming exercise of such exchange right with respect to all Common Shares held by Merck Healthcare KGaA), whereupon a number of Class C Shares belonging to Merck Healthcare KGaA equal to the number of Class A ordinary shares to be received by Merck Healthcare KGaA shall be surrendered by Merck Healthcare KGaA and, on surrender, automatically cancelled by the Issuer.

<sup>[4]</sup> This percentage assumes exchange of all Common Shares and surrender of all Class C Shares held by Merck Healthcare KGaA, Darmstadt Germany for a total of 3,330,231 Class A ordinary shares and is based upon 38,977,600 Class A ordinary shares outstanding as of November 14 2022 as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022. As of the date of this filing, the Class C shares held by Merck Healthcare KGaA, Darmstadt Germany represent 6.3% of the Issuer's total voting ordinary shares based upon 52,701,111 voting ordinary shares outstanding as of November 14, 2022 as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022, of which 38,977,600 shares were Class A ordinary shares and 13,723,511 shares were Class C ordinary shares.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Cusip No. G4444C102 | &nbsp;&nbsp;**13G** | &nbsp;&nbsp;Page 4 of 7 Pages |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. NAME OF REPORTING PERSONS E.Merck KG, Darmstadt Germany

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) □ (b) □

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION Germany

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; 5.<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SOLE VOTING POWER<br> 3,330,231<sup>[5]</sup><br>|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; 6.<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SHARED VOTING POWER<br> 0<br>|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; 7.<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SOLE DISPOSITIVE POWER<br> 3,330,231<sup>5</sup><br>|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; 8.<br>| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SHARED DISPOSITIVE POWER<br> 0 <br>|

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,330,231 <sup>5</sup>

10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE
 INSTRUCTIONS) □

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.9% <sup>[6]</sup>

12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO

------

<sup>[5]</sup> The record holder of the securities covered by this Schedule 13G is Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA Darmstadt, Germany. Merck Healthcare KGaA, Darmstadt Germany is a dominantly controlled subsidiary of Merck KGaA, Darmstadt, Germany and E.Merck KG, Darmstadt Germany. Merck KGaA, Darmstadt, Germany is a publicly traded company (Frankfurt Stock Exchange, DAX 40) and the beneficiary of Merck Healthcare KGaA, Darmstadt Germany. Merck KGaA, Darmstadt Germany is dominantly controlled by E.Merck KG, Darmstadt Germany. Merck Healthcare KGaA, Darmstadt Germany, currently holds 3,330,231 Class C ordinary shares of the Issuer (the "Class C Shares") and 99,000 Common Shares of MoonLake Immunotherapeutics AG, a Swiss stock corporation and subsidiary of the Issuer (the "Common Shares"). Pursuant to the terms of that certain Restated and Amended Shareholders' Agreement, dated April 5, 2022, between the Issuer, MoonLake Immunotherapeutics AG, Merck Healthcare KGaA, Darmstadt Germany, and the other parties named therein, which was attached as Exhibit 10.2 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 11, 2022 (the "Issuer Form 8-K") and is incorporated by reference herein, Merck Healthcare KGaA has the right, commencing October 05, 2022, to exchange such Common Shares for 3,330,231 Class A ordinary shares of the Issuer (assuming exercise of such exchange right with respect to all Common Shares held by Merck Healthcare KGaA), whereupon a number of Class C Shares belonging to Merck Healthcare KGaA equal to the number of Class A ordinary shares to be received by Merck Healthcare KGaA shall be surrendered by Merck Healthcare KGaA and, on surrender, automatically cancelled by the Issuer.

<sup>[6]</sup> This percentage assumes exchange of all Common Shares and surrender of all Class C Shares held by Merck Healthcare KGaA, Darmstadt Germany for a total of 3,330,231 Class A ordinary shares and is based upon 38,977,600 Class A ordinary shares outstanding as of November 14 2022 as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022. As of the date of this filing, the Class C shares held by Merck Healthcare KGaA, Darmstadt Germany represent 6.3% of the Issuer's total voting ordinary shares based upon 52,701,111 voting ordinary shares outstanding as of November 14, 2022 as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022, of which 38,977,600 shares were Class A ordinary shares and 13,723,511 shares were Class C ordinary shares.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; Cusip No. G4444C102 | &nbsp;&nbsp;**13G** | &nbsp;&nbsp;Page 5 of 7 Pages |

---

---

| | |
|:---|:---|
| **Item 1(a).** | **Name of Issuer:** |
|  | MoonLake Immunotherapeutics |
| **Item 1(b).** | **Address of Issuer's Principal Executive Offices:** |
|  | Dorfstrasse 29 |
|  | Zug, Switzerland 6300 |
| **Item 2(a).** | **Name of Person Filing:** |
|  | This Schedule 13G is being filed by each of the following persons (each, a "Reporting Person" and together, the "Reporting Persons"):<br>Merck Healthcare KGaA, Darmstadt, Germany an affiliate of Merck KGaA Darmstadt Germany<br> Merck KGaA, Darmstadt, Germany<br> E.Merck KG, Darmstadt, Germany<br>The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k)(l) of the Securities Exchange Act of 1934, as amended. |
| **Item 2(b).** | **Address of Principal Business Office or, if none, Residence:** |
|  | Merck Healthcare KGaA, Darmstadt, Germany an affiliate of Merck KGaA Darmstadt, Germany, and Merck KGaA: Frankfurter Strasse 250, 64293 Darmstadt, Germany<br> E.Merck KG: Emanuel-Merck-Platz 1, 64293 Darmstadt, Germany |
| **Item 2(c).** | **Citizenship:** |
|  | The Reporting Persons Merck Healthcare KGaA an affiliate of Merck KGaA Darmstadt Germany, Merck KGaA and E.Merck KG are organized in Germany. |
| **Item 2(d).** | **Title of Class of Securities:** |
|  | Class A ordinary shares, par value $0.0001 per share |
| **Item 2(e).** | **CUSIP Number:** |
|  | G4444C102 |
| **Item 3.** | **If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:** |
|  | <br> Not applicable |

---

(a) □ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b) □ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) □ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) □ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) □ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) □ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) □ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) □ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) □ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

(j) □ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k) □ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; Cusip No. G4444C102 | &nbsp;&nbsp;**13G** | &nbsp;&nbsp;Page 6 of 7 Pages |

---

---

| | |
|:---|:---|
| **Item 4.** | **Ownership:** |
|  | Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. |

---

(a) Amount beneficially owned: Each of the Reporting Persons may be deemed to beneficially own 3,330,231 Class A ordinary shares. See notes 1, 3 and 5 on the Cover Pages, which are incorporated herein.

(b) Percent of class: 7.9%; see notes 2, 4 and 6 on the Cover Pages, which are incorporated herein.

(c) Number of shares as to which the Reporting Persons have:

(i) Sole power to vote or to direct the vote: 3,330,231

(ii) Shared power to vote or to direct the vote: 0

(iii) Sole power to dispose or to direct the disposition of: 3,330,231

(iv) Shared power to dispose or to direct the disposition of: 0

---

| | |
|:---|:---|
| **Item 5.** | **Ownership of Five Percent or Less of a Class:** |
|  | If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following □. |
| **Item 6.** | **Ownership of More Than Five Percent on Behalf of Another Person:** |
|  | Not applicable |
| **Item 7.** | **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:** |
|  | Not applicable |
| **Item 8.** | **Identification and Classification of Members of the Group:** |
|  | Not applicable |
| **Item 9.** | **Notice of Dissolution of Group:** |
|  | Not applicable |
| **Item 10.** | **Certifications:** |
|  | **By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.** |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Cusip No. G4444C102 | &nbsp;&nbsp;**13G** | &nbsp;&nbsp;Page 7 of 7 Pages |

---

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | | | |
|:---|:---|:---|:---|
| **MERCK HEALTHCARE KGAA, DARMSTADT, GERMANY** an affiliate of Merck KGaA, Darmstadt, Germany | **MERCK HEALTHCARE KGAA, DARMSTADT, GERMANY** an affiliate of Merck KGaA, Darmstadt, Germany | **MERCK HEALTHCARE KGAA, DARMSTADT, GERMANY** an affiliate of Merck KGaA, Darmstadt, Germany | **MERCK HEALTHCARE KGAA, DARMSTADT, GERMANY** an affiliate of Merck KGaA, Darmstadt, Germany |
| Date: | January 26, 2023 | Date: | January 26, 2023 |
| By: | /s/ Matthias Muellenbeck | By: | /s/ Jens Eckhardt |
| Name: | Matthias Muellenbeck | Name: | Jens Eckhardt |
| Title: | SVP Business Development and Alliance Management | Title: | Head of Legal Business Development |

---

---

| | | | |
|:---|:---|:---|:---|
| **MERCK KGAA, DARMSTADT, GERMANY** | **MERCK KGAA, DARMSTADT, GERMANY** | **MERCK KGAA, DARMSTADT, GERMANY** | **MERCK KGAA, DARMSTADT, GERMANY** |
| Date: | January 26, 2023 | Date: | January 26, 2023 |
| By: | /s/ Jens Eckhardt | By: | /s/ Johannes Eckhardt |
| Name: | Jens Eckhardt | Name: | Johannes Eckhardt |
| Title: | Head of Legal Business Development | Title: | Senior Corporate Counsel |

---

---

| | | | |
|:---|:---|:---|:---|
| **E.MERCK KG, DARMSTADT, GERMANY** | **E.MERCK KG, DARMSTADT, GERMANY** | **E.MERCK KG, DARMSTADT, GERMANY** | **E.MERCK KG, DARMSTADT, GERMANY** |
| Date: | January 26, 2023 | Date: | January 26, 2023 |
| By: | /s/ Johannes Eckhardt | By: | /s/ Kristin Eibisch |
| Name: | Johannes Eckhardt | Name: | Kristin Eibisch |
| Title: | Attorney-in-Fact | Title: | Attorney-in-Fact |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Cusip No. G4444C102 | &nbsp;&nbsp;**13G** | &nbsp;&nbsp;Exhibits |

---

EXHIBIT INDEX

[Exhibit 99.1 Joint Filing Agreement, dated August 01, 2022, by and between Merck Healthcare KGaA an affiliate of Merck KGaA, Darmstadt, Germany, Merck KGaA, Darmstadt, Germany and E.Merck KG, Darmstadt, Germany.](https://www.sec.gov/Archives/edgar/data/1821586/000110465922085404/tm2222348d1_ex99-1.htm)